Powder: -20°C for 3 years | In solvent: -80°C for 1 year
(S)-Higenamine hydrobromide, an S-enantiomer of Higenamine, serves as the preliminary compound in benzylisoquinoline alkaloid biosynthesis. It is formed through the condensation of dopamine and 4-hydroxyphenylacetaldehyde (4-HPAA) via norcoclaurine synthase (NCS)[1].
产品描述 | (S)-Higenamine hydrobromide, an S-enantiomer of Higenamine, serves as the preliminary compound in benzylisoquinoline alkaloid biosynthesis. It is formed through the condensation of dopamine and 4-hydroxyphenylacetaldehyde (4-HPAA) via norcoclaurine synthase (NCS)[1]. |
体外活性 | The biosynthetic pathway leading to benzylisoquinoline alkaloids originates from the enzyme-catalyzed condensation of dopamine and 4-hydrophenylacetaldehyde to yield (S)-norcoclaurine. Both substrates are secondary metabolites derived from the decarboxylation/hydroxylation/deamination of tyrosine[1]. |
分子量 | 352.228 |
分子式 | C16H18BrNO3 |
CAS No. | 105990-27-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
(S)-Higenamine hydrobromide 105990-27-0 (S) Higenamine hydrobromide (S)Higenamine hydrobromide Higenamine Hydrobromide Inhibitor inhibitor inhibit